• Scientific Presentation
• Hotel del Coronado, San Diego, California
• January 7 - 9, 2008
• Symphogen participants: John Haurum, CSO - invited speaker; January 8 at 11:15 am

Symphogen's Sympress^TM technology enables manufacturing of target-specific recombinant polyclonal antibodies for therapeutic use. The preparation of this new class of drugs is based one a one-pot production strategy starting from a polyclonal cell bank consisting of multiple stable mammalian cell lines each expressing different individual antigen-specific antibodies. Clinical testing with the first drug product prepared by use of Sympress^TM was initiated in 2007. The employed polyclonal cell banking and characterization approach will be discussed.